Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Fusion Antibodies Plc (LSE:FAB) Draws Recovery Interest as Antibody Technology Offers Commercial Potential

Fusion Antibodies advanced by +6.61% in the reported session. The movement is better considered recovery interest following a difficult trading update than proof that business conditions have improved. Recent company commentary reported reduced revenue, weaker margins and a limited cash position.

Ankur Sharma | 19 October 2026

HemoGenyx Pharmaceuticals Plc (LSE:HEMO) Attracts Renewed Interest as Clinical Development Advances

The recent interim update described readiness for dose escalation, progress towards paediatric participation and development of European manufacturing arrangements. These provide a credible background for improving sentiment.

Ankur Sharma | 19 October 2026

Fusion Antibodies Shares Slump on AIM as Revenue Halves and Working Capital Review Begins (LSE:FAB)

Fusion Antibodies plc (LSE:FAB), the Belfast-based antibody discovery and engineering company quoted on the London Stock Exchange's AIM market and part of the FTSE AIM All-Share universe, is in sharp focus on 16 October 2026 following a dramatic sell-off a day earlier. On 15 …

Ankur Sharma | 19 October 2026

Fusion Antibodies Shares Stay Under Pressure After Sharp AIM Sell-Off as Cash Squeeze Meets Scientific Momentum (LSE:FAB)

Fusion Antibodies Plc (LSE:FAB), the Belfast-based antibody specialist quoted on AIM, was closely watched on Friday 16 October 2026 after a dramatic Thursday session, when the shares dropped by more than 41% to around 5.75p in morning trade after the company issued a combined …

Ankur Sharma | 19 October 2026

HemoGenyx Pharmaceuticals Keeps London Main Market Biotech Investors Watching as AML CAR-T Trial Moves to Higher Dose (LSE:HEMO)

HemoGenyx Pharmaceuticals Plc (LSE:HEMO), a clinical-stage biotechnology company whose shares trade on the Main Market of the London Stock Exchange, continues to draw attention from investors in mid-October 2026. No new price-sensitive statement dated Friday 16 October could be confirmed, but the stock stays …

Ankur Sharma | 19 October 2026

Avacta Group PLC (LSE:AVCT) in the Spotlight on AIM as £12.5m Raise, Interim Update and ESMO Countdown Put FTSE AIM All-Share Biotech Back on Watchlists

Avacta Group PLC (LSE:AVCT) heads into late October with a busy catalyst calendar, drawing attention from AIM investors on 16 October 2026. The company, which trades on the London Stock Exchange AIM market within the FTSE AIM All-Share universe, has just completed a fundraise, …

Ankur Sharma | 19 October 2026

SkinBioTherapeutics Shares Climb on AIM as Revenue Growth and Leadership Stability Lift Sentiment (LSE:SBTX)

SkinBioTherapeutics plc (LSE:SBTX) was again among the AIM healthcare names drawing attention on Friday 16 October 2026, as its shares finished the session at 6.00p, a rise of 4.35% on the day. The move followed a strong start to the week. On Monday 13 …

Ankur Sharma | 19 October 2026

ImmuPharma Shares Swing Below Key Trend Line as AIM Biotech Chases a P140 Lupus Partnering Deal Before Year End (LSE:IMM)

ImmuPharma plc (LSE:IMM), the AIM-listed specialty biopharmaceutical group, was back on traders' screens on Friday 16 October 2026 after its shares moved beneath their 200-day simple moving average. Small-cap AIM biotechs often trade on sentiment and partnering expectations rather than revenue, and this stock …

Ankur Sharma | 19 October 2026

Fusion Antibodies (LSE:FAB) Faces a Crucial Test After a Weak First Half

Fusion Antibodies is in focus after its 15 October AGM trading and research update. Unaudited revenue for the six months ended 30 September 2026 was approximately £457,000, compared with £838,000 a year earlier; gross margin was around 10%, versus 30%, and cash at period-end …

Ankur Sharma | 16 October 2026

ImmuPharma (LSE:IMM): Pipeline Progress Meets Funding and Clinical Risk

ImmuPharma remains a development-stage biotechnology story, with investors weighing pipeline progress against funding and clinical-development risk. Its interim results for the six months ended 30 June 2026 showed an operating loss of £1.1 million, compared with £1.2 million a year earlier. The reported overall …

Ankur Sharma | 16 October 2026
Support

Hi! How can we help you today?

Loading…